Dubey R K, Tyurina Y Y, Tyurin V A, Gillespie D G, Branch R A, Jackson E K, Kagan V E
Center for Clinical Pharmacology, Department of Medicine, University Hospital, Zurich, Switzerland.
Circ Res. 1999 Feb 5;84(2):229-39. doi: 10.1161/01.res.84.2.229.
The goal of this study was to test the hypothesis that antioxidant estrogens, by a mechanism independent of the estrogen receptor, protect phospholipids residing in the plasma membrane of vascular smooth muscle cells from peroxidation and peroxidation-induced cell growth and migration. Peroxidation of membrane phospholipids was assessed by HPLC analysis of phospholipids extracted from rat aortic vascular smooth muscle cells prelabeled with cis-parinaric acid (a fatty acid that is susceptible to peroxidation, which quenches its fluorescent properties). Incubation of cells for 2 hours with the peroxyl radical donor 2,2'-azobis-2,4-dimethylvaleronitrile (AMVN) caused peroxidation of all measured membrane phospholipids. This effect was attenuated by pretreating cells for 15 minutes with 50 to 5000 ng/mL of 2-hydroxyestradiol (strong antioxidant but weak estrogen-receptor ligand) or 4-hydroxytamoxifen (strong antioxidant and potent estrogen-receptor ligand), but not by estrone or droloxifene (both weak antioxidants but potent estrogen-receptor ligands). Moreover, pretreatment of cells for 20 hours with physiological concentrations (0.3 ng/mL) of 2-hydroxyestradiol or pharmacologically relevant concentrations of 4-hydroxytamoxifen (40 ng/mL) also decreased AMVN-induced phospholipid peroxidation. Both 2-hydroxyestradiol and 4-hydroxytamoxifen were as effective as 2,2,5, 7,8-pentamethyl-6-hydrochromane (an antioxidant homolog of vitamin E) in attenuating AMVN-induced peroxidation of membrane phospholipids. Also, physiological concentrations of 2-hydroxyestradiol, but not estrone, and pharmacologically relevant concentrations of 4-hydroxytamoxifen attenuated AMVM-induced DNA synthesis, cell proliferation, and cell migration. These studies demonstrate in vascular smooth muscle cells that antioxidant estrogens via a non-estrogen receptor-dependent mechanism attenuate peroxidation of membrane phospholipids and peroxidation-induced cell growth and migration.
抗氧化雌激素通过一种独立于雌激素受体的机制,保护血管平滑肌细胞质膜中的磷脂免受过氧化作用以及过氧化诱导的细胞生长和迁移。通过对用顺式-杷荏酸(一种易发生过氧化作用的脂肪酸,其荧光特性会淬灭)预标记的大鼠主动脉血管平滑肌细胞中提取的磷脂进行HPLC分析,来评估膜磷脂的过氧化作用。用过氧自由基供体2,2'-偶氮双-2,4-二甲基戊腈(AMVN)将细胞孵育2小时,会导致所有测定的膜磷脂发生过氧化。用50至5000 ng/mL的2-羟基雌二醇(强抗氧化剂但弱雌激素受体配体)或4-羟基他莫昔芬(强抗氧化剂且强效雌激素受体配体)预处理细胞15分钟,可减弱这种效应,但雌酮或屈洛昔芬(两者均为弱抗氧化剂但强效雌激素受体配体)则无此作用。此外,用生理浓度(0.3 ng/mL)的2-羟基雌二醇或药理相关浓度的4-羟基他莫昔芬(40 ng/mL)预处理细胞20小时,也可降低AMVN诱导的磷脂过氧化。2-羟基雌二醇和4-羟基他莫昔芬在减弱AMVN诱导的膜磷脂过氧化方面与2,2,5,7,8-五甲基-6-氢色满(维生素E的抗氧化同系物)效果相当。同样,生理浓度的2-羟基雌二醇(而非雌酮)以及药理相关浓度的4-羟基他莫昔芬可减弱AMVM诱导的DNA合成、细胞增殖和细胞迁移。这些研究在血管平滑肌细胞中证明,抗氧化雌激素通过非雌激素受体依赖性机制减弱膜磷脂的过氧化以及过氧化诱导的细胞生长和迁移。